Innate Pharma (IPH) investor relations material

Strategic focus and pipeline update

• Prioritized three assets: lacutamab, IPH4502, and monalizumab, with a streamlined organization and a 30% workforce reduction to align with the new strategy.

• Focused investment in high-value clinical assets and streamlined organization to support development and commercialization.

• Monalizumab, partnered with AstraZeneca, is in a Phase III study with milestone and royalty potential; IPH4502 is advancing in Phase I with early clinical activity.

Clinical and regulatory progress for lacutamab

• Lacutamab, a first-in-class anti-KIR3DL2 antibody, targets CTCL and has received FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations, as well as EMA PRIME, enhancing the pathway to approval and market exclusivity.

• TELEMAK/TELLOMAK Phase II data in Sezary syndrome and mycosis fungoides support accelerated approval, with confirmatory Phase III protocols submitted to the FDA and no new data required for SS approval.

• Accelerated approval for Sezary syndrome is targeted for 2027, with full approvals for both indications expected in 2029.

• Life cycle management includes expansion into peripheral T cell lymphoma and plans for first-line combination trials.

Clinical efficacy and safety

• In SS patients post-mogamulizumab, lacutamab achieved a global ORR of 42.9%, median PFS of 8.3 months, and median DoR of 25.6 months.

• In MF, lacutamab induced deep responses regardless of KIR3DL2 expression, with a global clinical benefit rate of 86% and median PFS of 10.2 months.

• Quality-of-life improvements were observed in both SS and MF, with early and sustained reductions in pruritus and Skindex-29 scores.

• Safety profile was favorable, with low discontinuation rates and manageable adverse events in both SS and MF populations.